Posted by Michael Wonder on 15 Feb 2018
Celltrion receives EU approval for trastuzumab biosimilar
14 February 2018 - Celltrion’s Herzuma (trastuzumab biosimilar) receives EU approval for early breast cancer, metastatic breast cancer, and metastatic gastric cancer
Celltrion announced today that the European Commission approved Herzuma (trastuzumab biosimilar) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumours have either HER2 over-expression or HER2 gene amplification.
The decision follows a positive opinion from the CHMP on 14 December 2017.
